Molecular Detection of Carbapenemase-Producing Acinetobacter baumannii Isolated From Intensive Care Units in Nigerian Tertiary Hospitals
Background
Acinetobacter baumannii has emerged as a significant healthcare-associated pathogen due to its ability to survive in hospital environments and develop resistance to multiple antimicrobial agents. Carbapenem-resistant strains represent a major clinical challenge because treatment options are often limited. Intensive care units are particularly vulnerable to outbreaks caused by resistant Acinetobacter species. Molecular surveillance of carbapenemase-producing isolates is critical for infection control and antimicrobial stewardship programs. This study seeks to investigate the prevalence and molecular characteristics of carbapenemase-producing Acinetobacter baumannii in intensive care units.
Research Objectives
- Determine the prevalence of Acinetobacter baumannii among ICU isolates.
- Identify carbapenem-resistant strains.
- Characterize carbapenemase genes using molecular methods.
- Assess antimicrobial susceptibility profiles.
- Evaluate risk factors associated with carbapenem-resistant infections.
Research Questions
- What is the prevalence of Acinetobacter baumannii in ICU settings?
- How common are carbapenem-resistant strains?
- Which carbapenemase genes are present among the isolates?
- What are the susceptibility profiles of the isolates?
- What factors are associated with carbapenem-resistant infections?
Suggested Methodology
Clinical specimens collected from ICU patients will be processed using standard microbiological methods. Antimicrobial susceptibility testing and molecular detection of carbapenemase genes will be conducted. Statistical analyses will evaluate risk factors and resistance characteristics.
Suggested Sample
Keywords
Need Help With Data Analysis?
Get support with statistical analysis, dashboards, interpretation, Chapter 4 reporting, and public health research analytics.